"Deep Bio...announced today that it has obtained marketing authorization from Swissmedic for DeepDx Prostate, its AI-powered prostate cancer diagnostic software."
"Deep Bio said Tuesday that its AI-based prostate cancer diagnostic auxiliary software, DeepDx Prostate, received a sales license from the Swiss medicines agency (Swissmedic) on Aug. 25."
"Deep Bio...announced that Dr. Lotan from Johns Hopkins Medicine presented their collaborative research which utilized the deep learning-based algorithm for prostate cancer diagnosis support at a podium session in the American Urological Association (AUA) annual meeting 2023...The study reassessed the diagnoses of 284 patients initially diagnosed as Gleason grade group 2 (Gleason score 3+4) and underwent radical prostatectomy at Johns Hopkins Medicine from 2000 to 2014."